Outcome |
Pharmacological interventions |
Physical interventions |
Psychological interventions |
Critical outcomes |
|
|
|
Pain intensity, posttreatment |
SMD −0.19, 95% CI −0.35 to −0.03, I2 = 0% 5 studies, 623 participants Moderate certainty |
SMD −0.60, 95% CI −1.15 to −0.04, I2 = 84% 6 studies, 374 participants Very low certainty |
SMD −0.29, 95% CI −0.43 to −0.16, I2 67% 38 studies, 3025 participants Low certainty |
Pain intensity, follow-up |
SMD −0.22, 95% CI −0.54 to 0.10, I2 = 0% 2 studies, 148 participants Very low certainty |
SMD −0.13, 95% CI −0.74 to 0.48, I2 = 73% 3 studies, 187 participants Very low certainty |
SMD −0.14, 95% CI −0.30 to 0.02, I2 = 61% 21 studies, 1881 participants Low certainty |
30% pain reduction, posttreatment |
RR 1.33, 95% CI 1.00 to 1.77, I2 = 0% 2 studies, 286 participants Very low certainty |
No studies |
No meta-analysis 1 study, 104 participants Very low certainty |
30% pain reduction, follow-up |
No studies |
No studies |
No meta-analysis 1 study, 104 participants Very low certainty |
50% pain reduction, posttreatment |
RR 1.71, 95% CI 1.13 to 2.58, I2 = 0% 2 studies, 286 participants Very low certainty |
No studies |
RR 2.11, 95% CI 1.61 to 2.77, I2 = 41%, 22 studies, 1140 participants Low certainty |
50% pain reduction, follow-up |
No meta-analysis 1 study, 29 participants Very low certainty |
No studies |
RR 2.09, 95% CI 1.29 to 3.38, I2 = 56% 9 studies, 445 participants Very low certainty |
Health-related quality of life, posttreatment |
No meta-analysis 1 study, 33 participants Very low certainty |
SMD −0.64, 95% CI −1.91 to 0.63, I2 = 89% 2 studies, 133 participants Very low certainty |
SMD −0.14, 95% CI −0.33 to 0.05, I2 = 57% 13 studies, 1397 participants Low certainty |
Health-related quality of life, follow-up |
No meta-analysis 1 study, 33 participants Very low certainty |
No studies |
SMD −0.09, 95% CI −0.35 to 0.16, I2 = 58% 7 studies, 795 participants Low certainty |
Functional disability, posttreatment |
No meta-analysis 1 study, 184 participants Very low certainty |
SMD −0.64, 95% CI −0.95 to −0.34, I2 = 0% 4 studies, 174 participants Very low certainty |
SMD −0.25, 95% CI −0.39 to −0.11, I2 = 60% 24 studies, 2358 participants Low certainty |
Functional disability, follow-up |
No studies |
No meta-analysis |
SMD −0.23, 95% CI −0.38 to −0.08, I2 = 55% 14 studies, 1755 participants Moderate certainty |
Role functioning, posttreatment |
No meta-analysis |
No meta-analysis |
SMD −0.21, 95% CI −0.52 to 0.10, I2 = 76% 9 studies, 856 participants Very low certainty |
Role functioning, follow-up |
No meta-analysis |
No meta-analysis |
SMD 0.14, 95% CI −0.32 to 0.60, I2 = 81% 4 studies, 476 participants Very low certainty |
Emotional functioning—depression, posttreatment |
SMD −0.06, 95% CI −0.25 to 0.14, I2 = 0% 3 studies, 389 participants Low certainty |
SMD −0.25, 95% CI −0.66 to 0.16, I2 = 0% 3 studies, 93 participants Very low certainty |
SMD −0.02, 95% CI −0.11 to 0.08, I2 = 0% 19 studies, 1781 participants High certainty |
Emotional functioning—depression, follow-up |
No meta-analysis |
No meta-analysis |
SMD 0.06, 95% CI −0.05 to 0.16, I2 = 0% 12 studies, 1375 participants High certainty |
Emotional functioning—anxiety, posttreatment |
SMD −0.07, 95% CI −0.30 to 0.16, I2 = 0% 2 studies, 299 participants Low certainty |
SMD 0.06, 95% CI −1.39 to 1.51, I2 = 86% 2 studies, 57 participants Very low certainty |
SMD −0.08, 95% CI −0.21 to 0.04, I2 = 44% 19 studies, 2031 participants Moderate certainty |
Emotional functioning—anxiety, follow-up |
No meta-analysis |
No studies |
SMD −0.07, 95% CI −0.17 to 0.03, I2 = 0% 13 studies, 1515 participants High certainty |
Sleep, posttreatment |
No studies |
No studies |
SMD 0.08, 95% CI −0.11 to 0.27, I2 = 0% 3 studies, 426 participants Low certainty |
Sleep, follow-up |
No studies |
No studies |
No meta-analysis 1 study, 269 participants Very low certainty |
Serious adverse events, posttreatment |
RD 0.00, 95% CI −0.01 to 0.01, I2 = 0% 4 studies, 1128 participants Very low certainty |
No studies |
No studies |
Adverse events, posttreatment |
RD 0.09, 95% CI −0.02 to 0.21, I2 68% 3 studies, 781 participants Very low certainty |
RD 0.01, 95% CI −0.04 to 0.05, I2 = 0% 4 studies, 161 participants Very low certainty |
No meta-analysis Very low certainty |
Important outcomes |
|
|
|
Activity participation, posttreatment |
No meta-analysis 1 study, 110 participants Very low certainty |
No meta-analysis 1 study, 54 participants Very low certainty |
No studies |
Activity participation, follow-up |
No studies |
No studies |
No meta-analysis 1 study, 44 participants Very low certainty |
Global judgement of satisfaction with treatment, posttreatment |
No meta-analysis 3 studies, 695 participants Very low certainty |
No studies |
SMD −0.43, 95% −0.60 to −0.26, I2 = 0% 6 studies, 535 participants Moderate certainty |
Global judgement of satisfaction with treatment, follow-up |
No meta-analysis 1 study, 115 participants Very low certainty |
No studies |
No meta-analysis 1 study, 269 participants Very low certainty |
Patient global impression of change, posttreatment |
No meta-analysis 1 study, 104 participants Very low certainty |
No meta-analysis 1 study, 42 participants Very low certainty |
No meta-analysis 1 study, 143 participants Very low certainty |
Patient global impression of change, follow-up |
No studies |
No studies |
No meta-analysis 1 study, 143 participants Very low certainty |
Fatigue, posttreatment |
No studies |
No studies |
No studies |
Fatigue, follow-up |
No studies |
No studies |
No studies |